Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial.

ABSTRACT:

Background and objectives

Large, randomized, controlled trials targeting higher hemoglobin level with erythropoiesis-stimulating agents for Western patients with CKD showed harm. However, the effect of anemia correction using erythropoiesis-stimulating agents may differ between CKD subpopulations. The Prevention of ESKD by Darbepoetin Alfa in CKD Patients with Non-diabetic Kidney Disease study, a multicenter, randomized, open-label, parallel-group study, aimed to examine the effect of targeting hemoglobin levels of 11-13 g/dl using darbepoetin alfa with reference to a low-hemoglobin target of 9-11 g/dl on kidney outcome in patients with advanced CKD without diabetes in Japan.

Design, setting, participants, & measurements

We enrolled 491 patients with CKD without diabetes, an

SUBMITTER: Hayashi T 

PROVIDER: S-EPMC7269223 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature